Spero Therapeutics, Inc. has made a notable move by granting stock options to its director, William Ho. This decision, filed on November 10, 2026, is significant as it may alter the company's ownership structure and reflects broader trends in the pharmaceutical preparations industry.

Background

Spero Therapeutics, Inc. operates within the pharmaceutical preparations sector, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol SPRO. Recent filings include an 8-K and a 10-Q submitted on November 12, 2026, indicating ongoing corporate activities and financial disclosures.

What the Filing Says

According to the recent filing (accession number 0001193125-26-455869), William Ho was granted a stock option allowing him to purchase 100,000 shares of common stock at an exercise price of $1.01 per share. The transaction date for this option is also noted as November 10, 2026. The shares underlying this option will vest in equal monthly installments until the third anniversary of the grant date, contingent on Ho's continued service.

Impact

This stock option grant may affect Spero Therapeutics' ownership dynamics, as Ho will own a total of 100,000 shares following the transaction. Such incentives are common in the pharmaceutical industry, where leadership is often rewarded with stock options to align their interests with those of shareholders.

What's Next

The filing does not say what happens next.